אביליפיי 30 מ"ג
bristol-myers squibb (israel) limited - aripiprazole 30 mg - tablets - aripiprazole - abilify is indicated for the treatment of schizophrenia. and for the treatment of moderate to severe manic episodes in bipolar i disorder and for the prevention of a new manic episode in patient who experienced predominantly manic episodes and whose manic episodes responded to aripiprazole treatment.
פרפלגן 10 מ"ג/מ"ל
bristol, myers squibb (israel) limited - paracetamol 10 mg/ml - solution for infusion - anilides - perfalgan is indicated for the short-term treatment of moderate pain, especially following surgery and for the short-term treatment of fever, when administration by intravenous route is clinically justified by and urgent need to treat pain or hyperthermia and/or when other routes of administration are not possible.
אופדואלג
bristol, myers squibb (israel) limited, israel - nivolumab; relatlimab - תרכיז להכנת תמיסה לאינפוזיה - relatlimab 4 mg/ml; nivolumab 12 mg/ml - nivolumab
קמזיוס 10 מג
bristol, myers squibb (israel) limited, israel - mavacamten - קפסולות - mavacamten 10 mg - mavacamten
קמזיוס 15 מג
bristol, myers squibb (israel) limited, israel - mavacamten - קפסולות - mavacamten 15 mg - mavacamten
קמזיוס 2.5 מג
bristol, myers squibb (israel) limited, israel - mavacamten - קפסולות - mavacamten 2.5 mg - mavacamten
קמזיוס 5 מג
bristol, myers squibb (israel) limited, israel - mavacamten - קפסולות - mavacamten 5 mg - mavacamten
סוטיקטו 6 מג
bristol, myers squibb (israel) limited, israel - deucravacitinib - טבליות מצופות פילם - deucravacitinib 6 mg - deucravacitinib
רייאטאז 150 מ"ג
bristol, myers squibb (israel) limited - atazanavir as sulfate 150 mg - capsules - atazanavir - reyataz is indicated in combination with other antiretroviral agents for the treatment of hiv-1 infection.
ברקלוד 0.5 מג
bristol - myers squibb, israel - entecavir; entecavir - טבליות מצופות פילם - entecavir 0.5 mg; entecavir 0.5 mg - entecavir - entecavir - baraclude is indicated for the treatment of chronic hepatitis b virus (hbv) infection in adults with compensated liver disease and evidence of active viral replication, and persistently elevated serum alanine aminotransferase (alt) levels. this indication is based on clinical trial data in patients with hbeag positive and hbeag negative hbv infection, nucleoside naive patients and patients with lamivudine-refractory hepatitis b.decompensated liver disease.